Major interaction on record — check this product against your medications before combining. Check your meds →
Dietary supplement

Resveratrol 200 mg Ingredients & Drug Interactions

by Protocol For Life Balance

Capsule Category: Botanical
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

Resveratrol 200 mg is a dietary supplement by Protocol For Life Balance with 2 active ingredients. Its ingredients are commonly taken for source of resveratrol, heart and circulation support, inflammation.Based on those ingredients, 1,377 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Red Wine Fruit Extract, Japanese Knotweed Rhizome, Root Extract. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Resveratrol 200 mg by Protocol For Life Balance

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • “Japanese Knotweed Rhizome, Root Extract” is listed as a grouped ingredient — the label gives one combined amount (400 mg) without saying how much of each component you get.

This supplement contains 2 active ingredients per capsule. Trans-resveratrol is a polyphenol compound that your body is meant to absorb and process, while red wine fruit extract brings resveratrol plus compounds naturally present in wine, including its alcohol content.

The inactive ingredients—hypromellose, microcrystalline cellulose, magnesium stearate, and silicon dioxide—are the capsule shell and binding agents that hold the tablet together; they're not meant to be active.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Cardiovascular support and heart health.
  • We looked for evidence on: Atherosclerosis, Cardiovascular disease (CVD), Congestive heart failure (CHF), Hypercholesterolemia, Hypertension, Unstable angina — and 3 related terms.
  • The strongest evidence on file: Wine is rated "Possibly Effective" for Cardiovascular disease (CVD) (Natural Medicines).
  • Also on file: Resveratrol is rated "Possibly Ineffective" for Cardiovascular disease (CVD), Hypercholesterolemia.
  • Also on file: Resveratrol is rated "Insufficient Reliable Evidence To Rate" for Hypertension.

Trans-resveratrol is possibly effective for obesity and allergic rhinitis (hay fever), but the evidence for cardiovascular disease and high cholesterol suggests it's possibly ineffective. Red wine fruit extract shows possibly effective evidence for Helicobacter pylori infection, weak bones (osteopenia), cardiovascular disease, and diabetes.

Keep in mind these ratings reflect the current state of the research—'possibly effective' means there's some promising data, not a guarantee, and you should discuss with your doctor whether this supplement makes sense for your specific situation.

The evidence, ingredient by ingredient Hu Zhang Resveratrol Wine

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Trans-resveratrol is generally well tolerated at typical supplement doses, but higher doses can cause digestive upset like diarrhea and loose stools. The safety data advises against this supplement during pregnancy and breastfeeding.

Red wine fruit extract contains alcohol, which carries its own health risks and can become habit-forming; it is not safe in any amount during pregnancy and passes into breast milk, so breastfeeding individuals should avoid it or discuss timing with their doctor. Some people may react to wine's sulfite and yeast content, especially those with asthma or a history of yeast allergy.

Side effects, ingredient by ingredient Hu Zhang Resveratrol Wine

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Resveratrol, Wine.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,374 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking this product, double-check with your pharmacist if you take erythromycin or other antibiotics, aspirin, warfarin or other blood thinners, cisapride, cyclosporine, disulfiram, phenytoin, or flibanserin—these carry Major-severity interaction risks with the red wine extract. Additionally, if you take medications metabolized by your liver's CYP2C19, CYP1A2, CYP3A4, or CYP2E1 enzymes, or any other blood-thinning medications, resveratrol may theoretically affect how your body processes them, though this remains largely unconfirmed in humans.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

This product may be worth considering if you're exploring options for hay fever or weak bones under your doctor's guidance—but the red wine extract means you're getting alcohol in capsule form, so it's not appropriate during pregnancy or breastfeeding. Anyone taking medications that interact with blood thinners, certain antibiotics, anti-seizure drugs, or immune suppressants should check their specific drugs with our tool before starting.

Talk to your pharmacist about whether it fits your health picture.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Mar 25, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Resveratrol 200 mg, straight from the product label.

Brand Protocol For Life Balance
Barcode (UPC) 707359133532
Net contents 60 Veg Capsule(s)
Market status On market
Date entered into DSLD Mar 25, 2025
DSLD ID 326474
Product type Botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Halal, Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Resveratrol 200 mg by Protocol For Life Balance, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Veg Capsule(s)
Maximum serving Sizes:
1 Veg Capsule(s)
Servings per container
60
UPC/BARCODE
707359133532
IngredientAmount% DV
Trans-Resveratrol200 mg--
Japanese Knotweed Rhizome, Root Extract400 mg--
Red Wine Fruit Extract10 mg--

Other ingredients: Hypromellose, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

Suggested usage: Take 1 capsule daily, or as directed by your healthcare practitioner.

Formula

How it works: Resveratrol is a polyphenol that is naturally found in the skin of red grapes, certain berries, and other plants. Recent research has shown that Resveratrol can support healthy cardiovascular function through its ability to quench free radicals, as well as through its ability to promote a healthy response to biological stress. Some studies indicate that Resveratrol may help to maintain a healthy cardiovascular function.

trans-Resveratrol Free radical scavenger

Crescent H (Halal)

Precautions

Cautions/Interactions: Women who have had breast cancer, or are at high risk, should consult a healthcare practitioner before using this product.

Resveratrol may interact with NSAIDs (including diclofenac), anticoagulant/antiplatelet medications, statins, calcium channel blockers, anti-arrhythmic agents, antihistamines, benzodiazepines, erectile dysfunction drugs, and HIV protease inhibitors. Consult your healthcare practitioner before use if taking any of these drugs.

This product may cause digestive upset in some sensitive individuals. If you experience any gastrointestinal discomfort after using this product, discontinue its use.

Contains sulfites.

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, tree nut or sesame ingredients. Produced in a GMP facility that processes other ingredients containing these allergens.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Formulation

Cardiovascular support

Non-GMO

Vegetarian/Vegan

Not manufactured with wheat, gluten, soy, milk, egg, fish, shellfish, tree nut or sesame ingredients.

Natural color variation may occur in this product.

FDA Statement of Identity

A Dietary Supplement

Storage

Store in a cool, dry place after opening.

Seals/Symbols

Crescent H (Halal)

See for yourself

Resveratrol 200 mg by Protocol For Life Balance label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Resveratrol 200 mg by Protocol For Life Balance

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Veg Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Japanese Knotweed Rhizome, Root Extract

Interacts with
826 drugs
400 mg per serving Form: Japanese Knotweed Rhizome Extract, Japanese Knotweed Root Extract

Hu Zhang (Japanese knotweed root) is a traditional Chinese herb that is one of the richest natural sources of resveratrol and emodin. Some lab and ear...

Japanese Knotweed Rhizome, Root Extract monograph & interactions

Red Wine Fruit Extract

Interacts with
926 drugs
10 mg per serving Form: Vitis vinifera Fruit Extract

Wine is an alcoholic beverage made from fermented grapes and is not a true dietary supplement or medicine. Despite popular claims about heart benefits...

Red Wine Fruit Extract monograph & interactions

Other (inactive) ingredients: Hypromellose, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Resveratrol 200 mg by Protocol For Life Balance Drug Interactions

Want to check YOUR meds against Resveratrol 200 mg?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,377Drugs
656 Major 721 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Resveratrol 200 mg with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Red Wine Fruit Extract37 drug types · 926 drugs

Aspirin

Concomitant use may increase the risk of gastrointestinal (GI) bleeding.
Concomitant use of aspirin with alcohol may increase the risk of GI bleeding.

Likelihood Probable Evidence C
Cisapride (Propulsid)

Concomitant use may increase blood alcohol levels and adverse effects.
Concomitant use of alcohol can increase blood alcohol levels and adverse effects. Also, red wine increases plasma cisapride concentrations, possibly by reducing metabolism.

Likelihood Probable Evidence B
Cns Depressants

Concomitant use may increase sedative and other adverse effects.
Concomitant use of alcohol with CNS depressants can increase sedative and other adverse effects, potentially through inhibition of the metabolism of certain CNS depressants.

Likelihood Likely Evidence C
Cyclosporine (Neoral, Sandimmune)

Red wine can reduce the levels and clinical effects of cyclosporine.
Red wine reduces plasma cyclosporine concentrations, possibly by reducing cyclosporine absorption. There is evidence the reduction in cyclosporine AUC by red wine is less in Asians (8% to 14%) than Caucasians (35% to 36%).

Likelihood Probable Evidence B
Disulfiram (Antabuse)

Concomitant use may cause a disulfiram reaction.
Disulfiram can cause a disulfiram reaction when taken with alcohol. Patients taking disulfiram should not consume any alcohol.

Likelihood Likely Evidence C
Erythromycin

Concomitant use may increase blood alcohol levels and adverse effects.
Concomitant use of erythromycin with alcohol can increase blood alcohol levels and adverse effects.

Likelihood Probable Evidence C
Felodipine (Plendil)

Consumption of red wine can rapidly increase felodipine levels and adverse effects.
Red wine taken on an empty stomach can cause "dose dumping" of extended-release felodipine, possibly by changing absorption or metabolism. Red wine can delay the appearance of felodipine in plasma until 4 hours after dosing and can rapidly increase its plasma concentration, producing peak serum levels 3 to 4 times higher than when felodipine is given with water. This can cause an increase in adverse effects 5 hours after dosing.

Likelihood Probable Evidence B
Flibanserin (Addyi)

Concomitant use increases the risk of severe hypotension and syncope.
Alcohol use is contraindicated in patients taking flibanserin due to the risk of severe hypotension and syncope.

Likelihood Probable Evidence A
Hepatotoxic Drugs

Concomitant use of alcohol with hepatotoxic drugs may increase the risk of hepatotoxicity.
Concomitant use of excessive amounts of alcohol with potentially hepatotoxic drugs can increase the risk of liver damage.

Likelihood Probable Evidence C
Monoamine Oxidase Inhibitors (Maois)

Concomitant use may cause hypertensive crisis.
Wine contains tyramine, which is metabolized by monoamine oxidase. Concurrent use of MAOIs with tyramine-containing beverages can lead to elevated levels of tyramine in the body. This can increase the effects of tyramine, which has been reported to cause hypertension, headache, and hypertensive crisis in numerous cases. Sensitivity to tyramine can increase up to 10-fold to 100-fold in people using an MAOI.

Likelihood Probable Evidence D
Nonsteroidal Anti-Inflammatory Drugs (Nsaids)

Concomitant use may increase the risk of gastrointestinal (GI) bleeding.
Concomitant use of NSAIDs with alcohol may increase the risk of GI bleeding.

Likelihood Probable Evidence C
Phenytoin (Dilantin)

Concomitant use may decrease the effectiveness of phenytoin.
Chronic, heavy alcohol use can induce the metabolism, reducing therapeutic effectiveness of phenytoin.

Likelihood Probable Evidence C
Warfarin (Coumadin)

Alcohol can alter the effects of warfarin, although the exact effect depends on the nature of alcohol consumption.
Acute alcohol intoxication can decrease metabolism and increase the effects of warfarin. In contrast, chronic, heavy alcohol use can induce metabolism of warfarin, reducing therapeutic effectiveness.

Likelihood Probable Evidence C
Acitretin (Soriatane)

Concomitant use increases the risk of long-term teratogenic effects.
Alcohol increases the transesterification of acitretin to etretinate, which is a teratogen that can remain in the body for years after discontinuation of acitretin. Patients of reproductive potential should avoid alcohol completely while taking acitretin and at least 2 months after discontinuation.

Likelihood Probable Evidence B
Antidiabetes Drugs

Concomitant use may interfere with blood glucose control.
Alcohol can impair gluconeogenesis and may increase the risk of acute hypoglycemia when used concomitantly with antidiabetes drugs. However, the carbohydrates in wine may also worsen glycemic control in patients with diabetes.

Likelihood Probable Evidence C
Antihypertensive Drugs

Theoretically, concomitant use may interfere with blood pressure control.
Clinical research suggests that consumption of alcohol can increase both systolic and diastolic blood pressure. However, acute alcohol intoxication can also increase the risk of hypotension and additive effects with antihypertensive drugs.

Likelihood Probable Evidence B
Bupropion (Wellbutrin)

Theoretically, concomitant use may increase the risk of adverse effects from alcohol.
In patients taking bupropion, there have been rare reports of adverse psychiatric events or reduced alcohol tolerance. Additionally, in chronic alcohol users, abrupt discontinuation of alcohol while taking bupropion may increase the risk of seizure.

Likelihood Possible Evidence D
Cefamandole (Mandol)

Concomitant use may cause a disulfiram-like reaction.
Cefamandole can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Possible Evidence C
Cefoperazone (Cefobid)

Concomitant use may cause a disulfiram-like reaction.
Cefoperazone can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Possible Evidence C
Cetirizine (Zyrtec)

Theoretically, concomitant use might increase the risk of CNS impairment.
Cetirizine may cause somnolence in some patients. There is some concern that taking cetirizine in conjunction with alcohol might reduce alertness and impair CNS performance.

Likelihood Possible Evidence D
Chlorpropamide (Diabinese)

Concomitant use may cause a disulfiram-like reaction.
Chlorpropamide can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Probable Evidence C
Citalopram (Celexa)

Theoretically, concomitant use might increase the risk of adverse effects from alcohol.
Some case reports suggest that citalopram may reduce alcohol tolerance and increase the risk of adverse effects from alcohol.

Likelihood Possible Evidence D
Doxycycline (Vibramycin)

Chronic alcohol use might reduce the levels and clinical effects of doxycycline.
Although acute alcohol ingestion does not seem to significantly impact the pharmacokinetics of doxycycline, chronic alcohol ingestion has been shown to significantly reduce the half-life and serum concentration of doxycycline.

Likelihood Possible Evidence B
Eluxadoline (Viberzi)

Chronic or excessive alcohol use might increase the risk of pancreatitis from eluxadoline.
In clinical studies, the risk of pancreatitis with eluxadoline was increased in chronic alcohol users and in those with acute intake of 3 or more alcoholic beverages daily.

Likelihood Possible Evidence A
Griseofulvin (Fulvicin)

Concomitant use may cause a disulfiram-like reaction.
Griseofulvin can cause a disulfiram-like reaction, including tachycardia and facial flushing, when taken with alcohol.

Likelihood Possible Evidence C

Japanese Knotweed Rhizome, Root Extract7 drug types · 826 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, hu zhang might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.
Hu zhang contains the constituent resveratrol. Resveratrol seems to have antiplatelet effects.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, hu zhang might increase levels of drugs metabolized by CYP1A2.
Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1A2 enzyme. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, hu zhang might increase levels of drugs metabolized by CYP2C19.
Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2C19 enzyme. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2E1 (Cyp2E1) Substrates

Theoretically, hu zhang might increase levels of drugs metabolized by CYP2E1.
Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2E1 enzyme. Also, a pharmacokinetic study shows that taking resveratrol 500 mg daily for 10 days prior to taking a single dose of chlorzoxazone 250 mg increases the maximum concentration of chlorzoxazone by about 54%, the area under the curve of chlorzoxazone by about 72%, and the half-life of chlorzoxazone by about 35%. Chlorzoxazone is used as a probe drug for CYP2E1.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, hu zhang might increase levels of drugs metabolized by CYP3A4.
Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP3A4 enzyme. However, a clinical study in adults with NAFLD found that adding resveratrol 3000 mg daily for 8 weeks did not necessitate dose adjustments to any established medications metabolized by CYP3A4.

Likelihood Possible Evidence D
Estrogens

Theoretically, hu zhang might competitively inhibit the effects of estrogen replacement therapy.
In vitro research shows that hu zhang might have estrogenic activity.

Likelihood Possible Evidence D
Carbamazepine (Tegretol)

Theoretically, hu zhang might increase the effects and adverse effects of carbamazepine.
In animals, blood and tissue levels of carbamazepine were increased when given in combination with hu zhang. It is thought that increased levels of carbamazepine are due to cytochrome P450 3A4 (CYP3A4) inhibition. This interaction has not been reported in humans.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Resveratrol 200 mg, from the product label.

Protocol For Life Balance

See all Protocol For Life Balance products
Name
Protocol For Life Balance
Street Address
395 S. Glen Ellyn Rd.
City
Bloomingdale
State
IL
ZipCode
60108
Web Address
protocolforlife.com
Pharmacist Counseling Corner

Resveratrol 200 mg by Protocol For Life Balance: Common Questions

Does Resveratrol 200 mg by Protocol For Life Balance interact with any medications?
Yes. Based on its ingredients, Resveratrol 200 mg has a known interaction with 1,377 medications, including 656 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Resveratrol 200 mg contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is resveratrol the same as red wine extract?
Not quite. Trans-resveratrol is a single compound found in grapes and red wine. Red wine fruit extract contains resveratrol plus other compounds naturally in wine, including alcohol. This product has both—the resveratrol for its polyphenol effects, and red wine extract which adds the wine compounds.
Can I take this if I'm pregnant?
No. The safety data advises against this supplement during pregnancy. If you're planning to conceive or are pregnant, talk with your doctor or pharmacist about safer options.
Will this help with my high cholesterol?
The evidence suggests resveratrol is possibly ineffective for high cholesterol, and red wine extract is possibly effective for weak bones and cardiovascular health, not cholesterol specifically. Ask your pharmacist whether this fits your goals.
What's the most common side effect?
At higher doses, digestive upset—diarrhea, loose stools, and stomach discomfort—is most common. The red wine extract can also cause side effects related to its alcohol content, like nausea, flushing, and drowsiness.
Is this safe if I'm breastfeeding?
No. The red wine extract's alcohol passes into breast milk, and the safety data advises against this supplement while breastfeeding. Talk with your doctor about alternatives.
What's in the capsule besides the active ingredients?
The capsule itself is hypromellose, and inside you'll find microcrystalline cellulose (a binder), magnesium stearate, and silicon dioxide—all standard inactive ingredients that help hold the capsule together.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Resveratrol 200 mg is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Resveratrol 200 mg label
Sources

Sources & How We Checked

Resveratrol 200 mg's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 116 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Resveratrol 24 references
  1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
  2. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. PubMed
  3. Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3.
  4. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.
  5. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8.
  6. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
  7. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. PubMed
  8. Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882.
  9. Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128(1):149-157.
  10. Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26(2):144-150.
  11. Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51(3):513-520.
  12. Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. PubMed
  13. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectro PubMed
  14. Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11(21):3171-3174. PubMed
  15. la, Porte C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., and Cameron, D. W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Cli PubMed
  16. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J., and Brenner, D. E. Repeat dose study of the cancer chemopreventive
  17. Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. PubMed
  18. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholic fatty
  19. Bedada SK, Neerati P. Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers. Phytother Res. 2016;30(3):463-8. PubMed
  20. Lin CT, Sun XY, Lin AX. Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail. 2016;38(2):214-21. PubMed
  21. Li Q, Yang G, Xu H, Tang S, Lee WY. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther 2021;21(1):214. PubMed
  22. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). Sci Rep 2022;12(1):10978. PubMed
  23. Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY. The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis. Med Clin (Barc) 2022;158(12):576-585. PubMed
  24. Badaoui A. Allergic contact dermatitis to resveratrol and Scutellaria baicalensis root extract in a cosmetic product. Contact Dermatitis 2022.

See these in context on the Resveratrol monograph →

Hu Zhang 19 references
  1. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. PubMed
  2. Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3.
  3. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.
  4. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8.
  5. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
  6. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. PubMed
  7. Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg Med Chem Lett 2001;11:1839-42. PubMed
  8. Zhang CZ, Wang SX, Zhang Y, et al. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol 2005;98:295-300. PubMed
  9. Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882.
  10. Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128(1):149-157.
  11. Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26(2):144-150.
  12. Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51(3):513-520.
  13. Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. PubMed
  14. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectro PubMed
  15. Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11(21):3171-3174. PubMed
  16. Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. PubMed
  17. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholic fatty
  18. Bedada SK, Neerati P. Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers. Phytother Res. 2016;30(3):463-8. PubMed
  19. Chi YC, Lin SP, Hou YC. A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats. Toxicol Appl Pharmacol 2012;263(3):315-22. PubMed

See these in context on the Hu Zhang monograph →

Wine 73 references
  1. Burnham TH, ed. Drug Facts and Comparisons, Updated Monthly. Facts and Comparisons, St. Louis, MO.
  2. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ 1999;318:1725-9. PubMed
  3. Offman EM, Freeman DJ, Dresser GK, et al. Cisapride interaction with grapefruit juice and red wine. Clin Pharmacol Ther 2000;67:110 (abstract PI-83).
  4. Tsunoda SM, Christians U, Velez RL, et al. Red wine (RW) effects on cyclosporine (CyA) metabolites. Clin Pharmacol Ther 2000;67:150 (abstract PIII-35).
  5. Tsunoda SM, Harris RZ, Velez RL, et al. Red wine (RW) effects on cyclosporine (CyA) Pharmacokinetics. Clin Pharmacol Ther 1998;65:159 (abstract PII-51). DOI
  6. Pearson TA. Alcohol and heart disease. Circulation 1996;94:3023-5. PubMed
  7. Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet 1997;33:79-90. PubMed
  8. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73. PubMed
  9. Vally H, de Klerk N, Thompson PJ. Alcoholic drinks: important triggers for asthma. J Allergy Clin Immunol 2000;105:462-7. PubMed
  10. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;337:1705-14.
  11. Goldberg I, Mosca L, Piano MR, Fisher EA. AHA Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the America
  12. Michaud DS, Giovannucci E, Willett WC, et al. Coffee and alcohol consumption and risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev 2001;10:429-37.
  13. Dufour MC. If you drink alcoholic beverages do so in moderation: what does this mean? J Nutr 2001;131:552S-61S. PubMed
  14. Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med 2002;162:569-74. PubMed
  15. Mukamal KJ, Longstreth WT, Mittleman MA. Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: the cardiovascular health study. Stroke 2001;32:1939-46. PubMed
  16. Bosetti C, La Vecchia C, Negri E, Franceschi S. Wine and other types of alcoholic beverages and the risk of esophageal cancer. Eur J Clin Nutr 2000;54:918-20. PubMed
  17. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-51. PubMed
  18. Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailabity. Clin Pharmacol Ther 2001;70:462-7.
  19. Bosetti C, La Vecchia C, Negri E, Franceschi S. Wine and other types of alcoholic beverages and the risk of esophageal cancer. Eur J Clin Nutr 2000;54:918-20. PubMed
  20. Kato H, Yoshikawa M, Miyazaki T, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. Cancer Lett 2001;167:65-72. PubMed
  21. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-51. PubMed
  22. Duncan BB, Chambless LE, Schmidt MI, et al. Association of the waist-to-hip ratio is different with wine than with beer or hard liquor consumption. Am J Epidemiol 1995;142:1034-8. DOI
  23. Bobak M, Skodova Z, Marmot M. Beer and obesity: a cross-sectional study. Eur J Clin Nutr 2003;57:1250-53. PubMed
  24. Koh-Banerjee P, Chu N, Spiegelman D, et al. Prospective study of the association of changes in dietary intake, physicial activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am J Clin Nutr 2003;78:719-27..
  25. Mennella J. Alcohol's effect on lactation. Alcohol Res Health 2001;25:230-4.
  26. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003;73:529-37. PubMed
  27. Launoy, G., Milan, C., Day, N. E., Faivre, J., Pienkowski, P., and Gignoux, M. Oesophageal cancer in France: potential importance of hot alcoholic drinks. Int J Cancer 6-11-1997;71(6):917-923. DOI
  28. Lijinsky, W. N-Nitroso compounds in the diet. Mutat.Res 7-15-1999;443(1-2):129-138. PubMed
  29. Seiler, C. [Alcohol, the heart and cardiovascular system]. Ther Umsch. 2000;57(4):200-204.
  30. Altieri, A., Bosetti, C., Gallus, S., Franceschi, S., Dal, Maso L., Talamini, R., Levi, F., Negri, E., Rodriguez, T., and La, Vecchia C. Wine, beer and spirits and risk of oral and pharyngeal cancer: a case-control study from Italy and Switzerland. Oral PubMed
  31. Bode, C. and Bode, J. C. Alcohol's role in gastrointestinal tract disorders. Alcohol Health Res World 1997;21(1):76-83.
  32. Zilkens, R. R., Burke, V., Hodgson, J. M., Barden, A., Beilin, L. J., and Puddey, I. B. Red wine and beer elevate blood pressure in normotensive men. Hypertension 2005;45(5):874-879. PubMed
  33. Mukamal, K. J., Maclure, M., Muller, J. E., and Mittleman, M. A. Binge drinking and mortality after acute myocardial infarction. Circulation 12-20-2005;112(25):3839-3845. PubMed
  34. Pehl, C., Wendl, B., and Pfeiffer, A. White wine and beer induce gastro-oesophageal reflux in patients with reflux disease. Aliment.Pharmacol Ther 6-1-2006;23(11):1581-1586. PubMed
  35. Chao, C. Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2007;16(11):2436-2447. PubMed
  36. Bushman, B. J. and Cooper, H. M. Effects of alcohol on human aggression: an integrative research review. Psychol.Bull 1990;107(3):341-354.
  37. Carstensen, J. M., Bygren, L. O., and Hatschek, T. Cancer incidence among Swedish brewery workers. Int J Cancer 3-15-1990;45(3):393-396. PubMed
  38. Potter, J. F., Watson, R. D., Skan, W., and Beevers, D. G. The pressor and metabolic effects of alcohol in normotensive subjects. Hypertension 1986;8(7):625-631. PubMed
  39. Puddey, I. B., Beilin, L. J., Vandongen, R., Rouse, I. L., and Rogers, P. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial. Hypertension 1985;7(5):707-713. PubMed
  40. Puddey, I. B., Beilin, L. J., Vandongen, R., and Rouse, I. L. A randomized controlled trial of the effect of alcohol consumption on blood pressure. Clin Exp Pharmacol Physiol 1985;12(3):257-261. PubMed
  41. Wellmann, K. F. ["Biere au cobalt". Remarks on the "Quebec myocardosis of beer drinker"]. Dtsch.Med Wochenschr. 3-15-1968;93(11):500-501.
  42. Bechetoille, A., Ebran, J. M., Allain, P., and Mauras, Y. [Therapeutic affect of zinc sulfate on central scotoma due to optic neuropathy of alcohol and tobacco abuse]. J Fr.Ophtalmol. 1983;6(3):237-242.
  43. Balazs, T. and Herman, E. H. Toxic cardiomyopathies. Ann Clin Lab Sci 1976;6(6):467-476.
  44. Lauwerys, R. and Lison, D. Health risks associated with cobalt exposure--an overview. Sci Total Environ 6-30-1994;150(1-3):1-6. PubMed
  45. Goldbohm, R. A., Van den Brandt, P. A., Van, 't, V, Dorant, E., Sturmans, F., and Hermus, R. J. Prospective study on alcohol consumption and the risk of cancer of the colon and rectum in the Netherlands. Cancer Causes Control 1994;5(2):95-104. PubMed
  46. Anderson, P., Cremona, A., Paton, A., Turner, C., and Wallace, P. The risk of alcohol. Addiction 1993;88(11):1493-1508.
  47. Leira, R. and Rodriguez, R. [Diet and migraine]. Rev Neurol. 1996;24(129):534-538.
  48. Glynn, S. A., Albanes, D., Pietinen, P., Brown, C. C., Rautalahti, M., Tangrea, J. A., Taylor, P. R., and Virtamo, J. Alcohol consumption and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 1996;7(2):214-223. PubMed
  49. Ferraroni, M., Decarli, A., Franceschi, S., and La, Vecchia C. Alcohol consumption and risk of breast cancer: a multicentre Italian case-control study. Eur J Cancer 1998;34(9):1403-1409. PubMed
  50. Chen JY, Zhu HC, Guo Q, et al. Dose-Dependent Associations between Wine Drinking and Breast Cancer Risk - Meta-Analysis Findings. Asian Pac J Cancer Prev. 2016;17(3):1221-33. PubMed
  51. Miura K, Zens MS, Peart T, et al. Alcohol consumption and risk of melanoma among women: pooled analysis of eight case-control studies. Arch Dermatol Res. 2015;307(9):819-28. PubMed
  52. Rivera A, Nan H, Li T, Qureshi A, Cho E. Alcohol Intake and Risk of Incident Melanoma: A Pooled Analysis of Three Prospective Studies in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1550-1558. PubMed
  53. Shufelt C, Merz CN, Yang Y, et al. Red versus white wine as a nutritional aromatase inhibitor in premenopausal women: a pilot study. J Womens Health (Larchmt). 2012;21(3):281-4. PubMed
  54. VanDenBerg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003;43(6):604-9. DOI
  55. Peet M, Yates RA, Carroll JA, Middlemiss DN. The interaction of tyramine with a single dose of tranylcypromine in healthy volunteers. Br J Clin Pharmacol. 1981;11(2):212-4. PubMed
  56. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry. 2007;68 Suppl 8:42-6.
  57. Miraghajani M, Momenyan S, Arab A, Hasanpour Dehkordi A, Symonds ME. Blueberry and cardiovascular disease risk factors: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2020;53:102389. PubMed
  58. German-Sanchez A, Alonso-Llamazares A, Garcia-Gonzalez F, Matala-Ahmed B, Bartolome-Zavala B, Antepara-Ercoreca I. Allergy to beer and wine caused by Saccharomyces cerevisiae in a patient sensitized to fungi. J Investig Allergol Clin Immunol 2021. PubMed
  59. Glucophage XR (metformin) prescribing information. Bristol-Myers Squibb Company. Princeton, NJ, May 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf
  60. Solosec (secnidazole) prescribing information. Lupin Pharmaceuticals, Inc. Baltimore, MD, January 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209363Orig1s014s016lbl.pdf
  61. Tindamax (tinidazole) prescribing information. Mission Pharmaceutical Company. San Antonio, TX, December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021618s008lbl.pdf
  62. Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother. 2020;64(3):e02167-19. PubMed
  63. Flagyl (metronidazole) prescribing information. Pfizer Labs. New York, NY, December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/012623s069lbl.pdf
  64. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. PubMed
  65. Flagyl (metronidazole) prescribing information [CANADA]. Odan Labs. Pointe-Claire, QC H9R 2Y6. January 2018. Available at: https://pdf.hres.ca/dpd_pm/00044072.PDF
  66. Addyi (flibanserin) prescribing information. Sprout Pharmaceuticals, Inc. Raleigh, NC, September 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022526s010lbl.pdf
  67. Soriatane (Acitretin) prescribing information. Stiefl Laboratories, Inc. Research Triangle Park, NC, September 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019821s028lbl.pdf
  68. Viberzi (Eluxadoline) prescribing information. Allergan USA, Inc. Irvine, CA, June 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206940s007lbl.pdf
  69. Chantix (Varenicline) prescribing information. Pfizer Labs, Inc. New York, NY, February 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021928s048lbl.pdf
  70. Zyrtec (Cetirizine) prescribing information. Pfizer Labs, Inc. New York, NY, October 2002. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19835s15,%2020346s8lbl.pdf
  71. Wellbutrin XL (Bupropion) prescribing information. GlaxoSmithKline LLC. Research Triangle Park, NC, March 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021515s044lbl.pdf
  72. Fetzima (Levomilnacipran) prescribing information. Allergan USA, Inc. Madison, NJ, September 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204168s007lbl.pdf
  73. Xyzal (Levocetirizine) prescribing information. UCB, Inc. April 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf

See these in context on the Wine monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring